Build-A-Bear Workshop has crossed a crucial threshold with its Relative Strength Rating now above 80. This upgrade underscores the retailer’s improving technical performance and hints at potential momentum in the competitive retail landscape.

CRISPR Therapeutics has crossed a key technical hurdle by surpassing an 80 Relative Strength Rating. The biotech company’s performance signals notable momentum in a competitive market space.

Salesforce’s recent share price of $236.58 and solid fundamentals have drawn attention from bullish investors. A closer look at its trailing P/E of 34.72 and forward P/E of 18.87 reveals a strong case for growth in the evolving cloud-based CRM market.